Advertisement

Topics

[Comment] Guadecitabine: a new therapeutic option for acute myeloid leukaemia?

02:10 EDT 25 Aug 2017 | The Lancet

The median age at presentation of patients with acute myeloid leukaemia is 67 years, which means that more than half the cases are in older individuals.1 For elderly patients who are not enrolled in experimental trials—the preferred option—treatments aimed at changing the natural course of the disease include conventional aggressive chemotherapy and the hypomethylating drugs azacitidine and decitabine. These drugs offer the possibility of achieving a clinical benefit even in the absence of a conventional complete remission, and for some patients, they might also serve as a bridge to allogeneic stem cell transplantation.

Original Article: [Comment] Guadecitabine: a new therapeutic option for acute myeloid leukaemia?

NEXT ARTICLE

More From BioPortfolio on "[Comment] Guadecitabine: a new therapeutic option for acute myeloid leukaemia?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...